DK0755684T3 - Vaccinekonjugat - Google Patents

Vaccinekonjugat

Info

Publication number
DK0755684T3
DK0755684T3 DK96111909T DK96111909T DK0755684T3 DK 0755684 T3 DK0755684 T3 DK 0755684T3 DK 96111909 T DK96111909 T DK 96111909T DK 96111909 T DK96111909 T DK 96111909T DK 0755684 T3 DK0755684 T3 DK 0755684T3
Authority
DK
Denmark
Prior art keywords
live virus
subject
neutralizing
vaccine conjugate
antibody
Prior art date
Application number
DK96111909T
Other languages
Danish (da)
English (en)
Inventor
Craig E Whitfill
Julius K Tyczkowski
James Paul Thaxton Jr
John A Dr Thoma
Tommy L Fredericksen
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Application granted granted Critical
Publication of DK0755684T3 publication Critical patent/DK0755684T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96111909T 1989-10-02 1990-10-01 Vaccinekonjugat DK0755684T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41603589A 1989-10-02 1989-10-02
US48067890A 1990-02-15 1990-02-15
US58685990A 1990-09-24 1990-09-24

Publications (1)

Publication Number Publication Date
DK0755684T3 true DK0755684T3 (da) 2001-08-20

Family

ID=27411077

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96111909T DK0755684T3 (da) 1989-10-02 1990-10-01 Vaccinekonjugat
DK90917281.9T DK0495008T3 (da) 1989-10-02 1990-10-01 Vaccinekonjugat til behandling af fuglesygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK90917281.9T DK0495008T3 (da) 1989-10-02 1990-10-01 Vaccinekonjugat til behandling af fuglesygdomme

Country Status (11)

Country Link
US (4) US5397569A (enExample)
EP (2) EP0495008B1 (enExample)
AT (2) ATE150976T1 (enExample)
AU (2) AU6714290A (enExample)
BR (1) BR9007702A (enExample)
CA (1) CA2066661C (enExample)
DE (2) DE69033728T2 (enExample)
DK (2) DK0755684T3 (enExample)
ES (2) ES2158200T3 (enExample)
IL (1) IL95867A (enExample)
WO (1) WO1991004749A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA93216B (en) * 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
JPH07206705A (ja) 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
US5807551A (en) * 1996-04-01 1998-09-15 Iowa State University Research Foundation, Inc. Method to provide artificial passive immunity in birds
IL128014A (en) * 1996-09-30 2003-11-23 Univ Arkansas Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
AU779403B2 (en) 1999-08-24 2005-01-20 Teva Pharmaceutical Industries Ltd. A vaccine composition and method of using the same
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
ZA200104596B (en) * 2000-06-09 2001-12-06 Akzo Nobel Nv IBDV strain for in ovo administration.
EP1161953A3 (en) * 2000-06-09 2004-02-04 Akzo Nobel N.V. IBDV strain for in OVO administration
US7037506B2 (en) 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US7029681B2 (en) 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
EP1546358A4 (en) 2002-03-22 2006-06-07 Zymogenetics Inc ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION
US6729265B2 (en) * 2002-06-27 2004-05-04 Arkion Life Sciences Llc Supplemented antibody feed to enter the circulating system of newborns
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
WO2008147847A1 (en) * 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
US10335484B2 (en) 2013-01-08 2019-07-02 Humabs Biomed Sa Methods of generating robust passive and active immune responses
CN103341164B (zh) * 2013-07-19 2015-06-24 天津瑞普生物技术股份有限公司 一种鸡传染性法氏囊病抗原抗体复合物、制剂及制备方法
CN114616325A (zh) 2019-09-11 2022-06-10 硕腾服务有限责任公司 表达禽病原体抗原的重组火鸡疱疹病毒载体和其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2518978A (en) * 1946-09-12 1950-08-15 American Cyanamid Co Hog cholera vaccine
DE1041214B (de) * 1957-03-11 1958-10-16 Dr Med Karl Theurer Verfahren zur Herstellung von Impfstoffen gegen Viruserkrankungen
US3846543A (en) * 1963-01-02 1974-11-05 Monsanto Co Process for the separation of virus from non-viral proteins
US3326767A (en) * 1966-03-21 1967-06-20 Abbott Lab Avian leukosis treatment with inactivated rous sarcoma virus
US3651213A (en) * 1969-05-29 1972-03-21 Monsanto Co Method for the immunization of a living animal body against viral disease
US3853467A (en) * 1973-08-15 1974-12-10 Gen Electric Method and apparatus for immunological detection of biological particles
CA1039649A (en) * 1973-08-30 1978-10-03 General Electric Company Method of forming multilayer immunologically complexed films
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
EP0073856A1 (en) * 1981-08-28 1983-03-16 Gist-Brocades N.V. Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4493825A (en) * 1982-10-05 1985-01-15 Iowa State University Research Foundation Purified and antigenically selective vaccines for domestic animals
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US4956452A (en) * 1987-06-14 1990-09-11 The University Of Maryland Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus
US4867975A (en) * 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors

Also Published As

Publication number Publication date
WO1991004749A1 (en) 1991-04-18
ES2158200T3 (es) 2001-09-01
AU6714290A (en) 1991-04-28
ATE200735T1 (de) 2001-05-15
DE69033728D1 (de) 2001-05-31
AU6755990A (en) 1991-04-28
IL95867A (en) 1994-10-07
EP0495008A1 (en) 1992-07-22
DE69030383D1 (de) 1997-05-07
US5397569A (en) 1995-03-14
ES2102368T3 (es) 1997-08-01
AU641958B2 (en) 1993-10-07
EP0755684B1 (en) 2001-04-25
US6299874B1 (en) 2001-10-09
BR9007702A (pt) 1992-08-18
CA2066661C (en) 2001-05-08
ATE150976T1 (de) 1997-04-15
US6136319A (en) 2000-10-24
US5871748A (en) 1999-02-16
DK0495008T3 (da) 1997-10-13
EP0495008A4 (en) 1993-05-05
IL95867A0 (enExample) 1991-07-18
DE69030383T2 (de) 1997-10-23
EP0755684A1 (en) 1997-01-29
DE69033728T2 (de) 2001-11-22
EP0495008B1 (en) 1997-04-02
CA2066661A1 (en) 1991-04-03

Similar Documents

Publication Publication Date Title
DE69033728D1 (de) Impfstoffkonjugat
CA2116348A1 (en) Sirs vaccine and diagnosis method
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
LU91396I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
LU91323I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
AU4055989A (en) Novel infectious bursal disease virus
ES548397A0 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
FI955150L (fi) OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistamiseksi
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE3889581D1 (de) Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung.
DE69333730D1 (de) Impfstoff, der acemannan als adjuvans enthält
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
AU6605190A (en) Novel infectious bursal disease virus
ATE39055T1 (de) Verfahren zur immunisierung von schweinen gegen die aujeszky-krankheit.
KR920007636A (ko) 신규의 백신체
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
RU93052279A (ru) Способ лечения инфекционных заболеваний
Epstein The Vaccine Control of Virus-Induced Cancers
RU96123906A (ru) Способ и вакцина для профилактики и лечения иммунодефицитов, например рака
RU96108623A (ru) Штамм coronavirus canine используемый для контроля иммуногенной активности вакцин и получения сывороток для лечения и диагностики коронавирусной инфекции собак
ATE99956T1 (de) Newcastle-krankheitsvirus-impfstoff und methode fuer seine verwendung.